Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Your Impact
    • How You Can Help
    • Events

Funded Grants

Back to results

ShARP: Screenable assays for RNA-binding proteins involved in brain disorders and diseases

Project Overview

Brain disorders such as autism, major depressive disorder and Alzheimer’s disease are among the greatest medical challenges of our era. Many drugs targeting the central nervous system (CNS) have been developed to modulate G protein-coupled receptors, ion channels or transporters with mitigated success. There remains a shortage of disease-relevant targets that can be harnessed for drug discovery to treat the onset and progression of brain disorders/diseases. This project focuses on RNA-binding proteins as untapped therapeutic targets because of their important role in the brain. Members of the RNA-binding protein family provide powerful post-transcriptional control over cellular phenotype by regulating up to 30% of the variation of the cellular proteome. Recent human genetic studies further implicate RNA-binding proteins in many neurodevelopmental, neuropsychiatric disorders and neurodegenerative diseases.

The team will develop a first-in-kind sensitive, adaptable, and validated HTS platform called ShARP for Screenable Assays for RNA-bindingProteins. This platform is based on the use of specific untranslated regions (UTRs) that are targeted by RNA-binding proteins to modulate recruitment of mRNA to ribosomes during protein synthesis. The principal reporter readout will be luminescence and is thus compatible with existing technologies and instrumentation. There are presently no effective tools to explore the usefulness of RNA-binding proteins for drug development. This platform will have major benefits for the biopharmaceutical industry as it will promote new drug target identification, aid with the drug discovery/screening process and promote optimization and validation of promising first-in-class CNS-relevant drugs to treat challenging brain diseases.

Content from CQDM: https://www.cqdm.org/en/projects-portfolio/project/67

 

 

Principal Investigator

Martin Beaulieu , University of Toronto

Partners and Donors

CQDM

Project Ongoing

ShARP: Screenable assays for RNA-binding proteins involved in brain disorders and diseases

  • Program Type

    Platform grants

  • Area of research

    Neurotechnology

  • Disease Area

    Other

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Ontario

  • Start Date

    2016

  • Total Grant Amount

    $1,477,008

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations.

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign up

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co